• No results found

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process

N/A
N/A
Protected

Academic year: 2020

Share "The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process"

Copied!
6
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Fig. 1 Summary of the production and testing of virus challenge agents

References

Related documents

The ensuing rush for mining concessions in Katanga has pitted artisanal miners ( creuseurs ) against the Congolese state and its partners: foreign mining companies.. Beginning in

The IL28B quality polymorphism is the most grounded indicator of treatment reaction and unconstrained viral leeway in hepatitis C genotype 1 infection.. Consequently,

4 Only mutations : Early mutation induced by the therapy 5 Mutations and switches : Polymorphic Evolution Sequence.

ABSTRACT: Distribution and movement patterns of Antarctic blue whales Balaenoptera musculus intermedia at large temporal and spatial scales are still poorly understood. The objective

We graded risk of attrition bias for the success of soft tissue anaes- thesia, measured by the absence of pain during a procedure as- sessed on a VAS or by other appropriate

Keywords: biology, explanation, integration, mechanisms, pluralism, reduction, scientific aims,.. scientific practice,

Regeneration of endogenous dorsal column axons Transplantation of GDAs into stab-wound lesions of the dorsal column white matter pathways of adult rat spinal cord (Figure

To begin to address this knowledge gap, the present study tracked Shigella infections in the largest infectious hospital in Beijing over a period of 17 years (1994 to 2010),